Evaluation of Paraoxonase 1 Activities in Patients Infected with Hepatitis C Virus Genotype 1b and Genotype 4 in the Kayseri Province of Turkey

• Published in: Viral hepatit dergisi 2015-04, Vol.21 (1)
• Main Authors: SARIGÜZEL, Fatma Mutlu, KARAKÜKCÜ, Çigdem, KOÇER, Derya, KARAMAN, Hatice, KARAMAN, Ahmet, YAMAN, Ozan, GÖDEKMERDAN, Ahmet
• Format: Article
• Language: English
• Subjects: Antioxidants; Enzymes; Genotype & phenotype; Hepatitis
• ISSN: 1307-9441; 2147-2939
• DOI: 10.4274/vhd.65256

Objective: Hepatitis C virus (HCV) infection is an important cause of chronic liver disease and is associated with oxidative stress. The type of treatment given for chronic HCV infection depends on the genotype of the virus. Genotype 1b is known to be associated with poor prognosis, although knowledge about genotype 4 is not sufficient. In this study, we aimed to compare serum paraoxonase (PON1) activities in HCV genotype 1b-infected patients with those in HCV genotype 4-infected ones, and the relationship of PON1 activity with hepatic damage demonstrated as liver fibrosis. Materials and Methods: In this study, we included 49 patients with HCV genotype 1b and 42 with genotype 4. Serum PON1 activity was analyzed by spectrophotometric method. Serum triglycerides, total cholesterol, LDL, HDL, and transaminases levels and liver histological activity index (HAI) and fibrosis scores were evaluated retrospectively. Results: Serum PON1 activity was significantly lower in genotype 1b compared to that in genotype 4 (147.6±73.9U/L and 192.6±99.0 U/L, respectively; p=0.015). There was no significant correlation between PON1 activity and HCV RNA viral load and fibrosis scores (p>0.05). However, there was no difference in the other serum parameters between the two genotypes (p>0.05). Conclusion: Antioxidant enzyme PON1 activity is lower in genotype 1b compared to that in genotype 4. This may affect response to therapy and prognosis. Further studies with larger samples are needed to understand the association between PON1 activity and HCV genotypes to elucidate if PON1 activity could be a prognostic factor.